Author(s): Sandhya Jain, Surya Prakash Gupta

Email(s): suryatony@yahoo.co.in

DOI: 10.52711/0974-360X.2024.00631   

Address: Sandhya Jain, Surya Prakash Gupta*
Rajiv Gandhi Institute of Pharmacy, Faculty of Pharmaceutical Science and Technology, AKS University, Satna (MP) India.
*Corresponding Author

Published In:   Volume - 17,      Issue - 8,     Year - 2024


ABSTRACT:
Quinoxaline is a heterocyclic compound with a benzene ring fused to a pyrazine ring. It learned much about his ability to cure many diseases, including cancer. Phosphoinositide 3kinase (PI3K) and the mTOR (mammalian target of rapamycin) are the 3 essential pathways which regulate the growth, survival, and development of cells. Dysregulation of such pathways is often seen in cancer, making them attractive targets for cancer therapy. In particular, several quinoxaline derivatives show promise as two inhibitors of the mTOR/PI3K signalling pathway, which is often dysregulated in cancer along with many other diseases. One such example is PX866, which has shown activity against several cancers in previous studies. In previous studies, another quinoxaline derivative, PKI587, also showed strong inhibitory activity against mTOR and PI3K. PKI587 was researched in several clinical trials for treating many cancer types, which include non-small cell lung as well as breast cancer. Dual inhibitors of mTOR and PI3K, including quinoxaline derivatives, inhibit cell growth and cancer by blocking the signalling of these two important factors. In recent years, quinoxaline derivatives have emerged as potent dual inhibitors of PI3K and mTOR, and in this review, we explore the latest developments in this area.


Cite this article:
Sandhya Jain, Surya Prakash Gupta. Sandhya Jain, Surya Prakash Gupta. Cancer Therapy with Quinoxaline Derivatives: Dual Inhibition of Pi3k and Mtor Signaling Pathways. Research Journal of Pharmacy and Technology.2024; 17(8):4068-4. doi: 10.52711/0974-360X.2024.00631

Cite(Electronic):
Sandhya Jain, Surya Prakash Gupta. Sandhya Jain, Surya Prakash Gupta. Cancer Therapy with Quinoxaline Derivatives: Dual Inhibition of Pi3k and Mtor Signaling Pathways. Research Journal of Pharmacy and Technology.2024; 17(8):4068-4. doi: 10.52711/0974-360X.2024.00631   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-8-79


REFERENCES:
1.    Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumours. Journal of Clinical Oncology. 2012; 30(3): 282-290.
2.    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, et al. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020; 38(10): 1059–69. doi:  10.1200/JCO.19.01027
3.    Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, et al. A Phase I/II Study of Pemetrexed with Sirolimus in Advanced, Previously Treated Non-Small Cell Lung Cancer. Transl Lung Cancer Res. 2019; 8(3): 247–57. doi:  10.21037/tlcr.2019.04.19   
4.     Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, et al. Phase I/II Trial of Temsirolimus Combined with Interferon Alfa for Advanced Renal Cell Carcinoma. J Clin Oncol 2007; 25(25): 3958–64. doi:  10.1200/JCO.2006.10.5916  
5.    Fan Y, Sun T, Shao Z, Zhang Q, Ouyang Q, Tong Z, et al. Effectiveness of Adding Everolimus to the First-Line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021; 7(10): e213428. doi:  10.1001/jamaoncol.2021.3428  
6.    Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, et al. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(11): 1556–64. doi:  10.1001/jamaoncol.2019.2526  
7.    Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, et al. Phase I or II Study of Ribociclib in Combination with Topotecan-Temozolomide or Everolimus in Children with Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial. J Clin Oncol. 2021; 39(32): 3546–60. doi:  10.1200/JCO.21.01152  
8.    Morscher RJ, Brard C, Berlanga P, Marshall LV, Andre N, Rubino J, et al. First-In-Child Phase I/II Study of the Dual Mtorc1/2 Inhibitor Vistusertib (AZD2014) as Monotherapy and in Combination with Topotecan-Temozolomide in Children with Advanced Malignancies: Arms E and F of the AcSe-ESMART Trial. Eur J Cancer. 2021 157: 268–77. doi:  10.1016/j.ejca.2021.08.010  
9.    Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, et al. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021; 27(12): 3329–38. doi:  10.1158/1078-0432.CCR-20-4131  
10.    Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci. 2021; 22(7): 3464. doi:  10.3390/ijms22073464  
11.    Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT et al.  Stand Up to Cancer Phase Ib Study of Pan-phosphoinositide-3-kinase Inhibitor Buparlisib with Letrozole in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 2014; 32(12): 1202-1209.
12.    Wallin JJ, Edgar KA, Guan J, Amici L, Shepherd R, Hembrough T et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Molecular Cancer Therapeutics. 2011; 10(12): 2426-2436.
13.    Engelman JA., Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer. 2009; 9(8): 550-562.
14.    Laplante M, Sabatini DM.., mTOR signaling in growth control and disease. Cell. 2012; 149(2): 274-293.
15.    Fruman DA, Rommel C., PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery. 2014; 13(2): 140-156.
16.    Zhao L, Vogt PK., Helical domain and kinase domain mutations in p110α of phosphatidylinositide 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences. 2008; 105(7): 2652-2657.
17.    Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature Reviews Cancer. 2015; 15(1): 7-24
18.    Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics. 2004; 3(8): 763-772.
19.    Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008; 27(41): 5511-5526.
20.    García-Martínez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. British Journal of Cancer. 2011; 104(7): 1116-1125.
21.    Cook SJ. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer. 2014; 14(11): 736-750.
22.    Tan AC, Heiser LM, Lababidi S, Kluza J, Gulbahce N, Eschrich SA, Friend SH. PI3K pathway inhibitors sensitize prostate cancer cells to doxorubicin-induced apoptosis. Oncotarget. 2016; 7(28): 45608-45621.
23.    Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. Journal of Biological Chemistry. 2000; 275(32): 24500-24505.
24.    Park S, Chapuis N, Saintigny P, Rejiba S, Abati K, Gongora C, Lizard-Nacol S. Dihydro artemisinin potentiates the radiosensitivity of breast cancer cells by inducing autophagy. Oncology Reports. 2014; 31(3): 1375-1381.
25.    16.Hua Y, Ma X, Liu X, et al. Design, synthesis and biological evaluation of novel quinoxaline derivatives as PI3K/mTOR dual inhibitors. European Journal of Medicinal Chemistry. 2019; 183: 111706.
26.    Kim Y, Kim J, Kim H, et al. Quinoxaline derivatives as potential dual inhibitors of PI3K and mTOR for the treatment of cancer. Bioorganic and Medicinal Chemistry Letters. 2016; 26(2): 469-474.
27.    Clinical Trials.gov. Accessed March 1, 2023. https://clinicaltrials.gov/
28.    Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery. 2014; 13(2): 140-156. doi:10.1038/nrd4204
29.    Manning BD, Toker A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3): 381-405. doi: 10.1016/j.cell.2017.04.001
30.    Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 169(2): 361-371. doi: 10.1016/j.cell.2017.03.035
31.    Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3): 179-183. doi: 10.1016/j.ccr.2005.08.007
32.    Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine. 2016; 67(1): 11-28. doi:10.1146/annurev-med-062913-051343
33.    Wallin JJ, Edgar KA, Guan J, et al. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 2012; 31(15): 1923-1935. doi:10.1038/onc.2011.386
34.    Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition withAlpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results from the First-in-Human Study. Journal of Clinical Oncology. 2018; 36(13): 1291-1299. doi:10.1200/JCO.2017.75.3077
35.    Folkes AJ, Ahmadi K, Alderton WK, et al. The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d] pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. Journal of Medicinal Chemistry. 2008; 51(18): 5522-5532. doi:10.1021/jm800295d
36.    Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences. 2015; 36(2): 124-135. doi: 10.1016/j.tips.2014.12.001
37.    Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery. 2009; 8(8): 627-644. doi:10.1038/nrd2926
38.    Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget. 2012; 3(4): 371-394. doi: 10.18632/oncotarget.488
39.    Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results from the First-in-Human Study. Journal of Clinical Oncology. 2018; 36(13): 1291-1299. doi:10.1200/JCO.2017.75.3077
40.    Gökmen-Polar Y, Neelamraju Y, Goswami CP, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in ovarian cancer. Cancer Research. 2018; 78(13 Supplement): Abstract nr 1867. doi: 10.1158/1538-7445.AM2018-1867
41.    Xu RH, Wei W, Krawczyk M, et al. Combining Targeted Therapy and Immune Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. Cancer Biology and Medicine. 2014; 11(4): 237-246. doi: 10.7497/j.issn.2095-3941.2014.04.001
42.    Zou CY, Smith KD. Pinpointing PI3K pathway targets: a matter of context and control. Science Signaling. 2013; 6(289): 49. doi: 10.1126/scisignal.2004553





Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available